Suppr超能文献

["《儿科 COVID-19》临床实践指南中的主要变化"]

[Main changes in the «COVID-19 in paediatrics» clinical practice guideline].

作者信息

González de Dios Javier, Martínez Rubio Victoria, Giménez Díaz de Atauri Álvaro, Ochoa Sangrador Carlos, Rodríguez-Salinas Pérez Enrique, Flores Villar Sergio, Cuervo Valdés Jaime Javier

机构信息

Servicio de Pediatría, Hospital General Universitario de Alicante. Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, España.

Centro de salud Los Fresnos, Torrejón de Ardoz, Madrid, España.

出版信息

An Pediatr (Barc). 2022 Aug;97(2):129.e1-129.e8. doi: 10.1016/j.anpedi.2022.06.015. Epub 2022 Jun 28.

Abstract

We present a summary of the main modifications to the «COVID-19 in Paediatrics» clinical practice guideline made from its initial version, published in 2021, and the version published in 2022. The document was developed following the structured steps of evidence-based medicine and applying the GRADE system to synthesize the evidence, assess its quality and, when appropriate, issue graded recommendations (based on the quality of the evidence, values and preferences, the balance between benefits, risks and costs, equity and feasibility). This update also includes the modifications proposed by external reviewers.We summarised the main modifications in the following sections: epidemiology, clinical features, diagnosis, prevention, treatment and vaccines. In relation to the body of knowledge achieved in the first year of the pandemic, the literature published in the second year contributed additional data, but without substantial modifications in many of the areas. The main changes took place in the field of vaccine research. This update was completed in December 2021, coinciding with the emergence of infections by the omicron variant, so the document will need to be updated in the future.

摘要

我们总结了《儿科 COVID-19》临床实践指南从 2021 年发布的初始版本到 2022 年发布版本的主要修改内容。该文件是按照循证医学的结构化步骤制定的,并应用 GRADE 系统来综合证据、评估其质量,并在适当的时候发布分级推荐(基于证据质量、价值观和偏好、收益、风险和成本之间的平衡、公平性和可行性)。此次更新还包括外部评审员提出的修改意见。我们在以下部分总结了主要修改内容:流行病学、临床特征、诊断、预防、治疗和疫苗。关于疫情第一年所取得的知识体系,第二年发表的文献提供了更多数据,但许多领域没有实质性修改。主要变化发生在疫苗研究领域。此次更新于 2021 年 12 月完成,恰逢奥密克戎变种感染出现,因此该文件未来需要更新。

相似文献

1
[Main changes in the «COVID-19 in paediatrics» clinical practice guideline].
An Pediatr (Barc). 2022 Aug;97(2):129.e1-129.e8. doi: 10.1016/j.anpedi.2022.06.015. Epub 2022 Jun 28.
2
Main changes in the "COVID-19 in paediatrics" clinical practice guideline.
An Pediatr (Engl Ed). 2022 Aug;97(2):129.e1-129.e8. doi: 10.1016/j.anpede.2022.06.006. Epub 2022 Jul 7.
3
[COVID-19: Critical appraisal of the evidence].
An Pediatr (Barc). 2021 Sep;95(3):207.e1-207.e13. doi: 10.1016/j.anpedi.2021.05.019. Epub 2021 Jun 3.
4
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
6
Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary.
Otolaryngol Head Neck Surg. 2019 Aug;161(2):195-210. doi: 10.1177/0194599819859883.
7
ESHRE guideline: recurrent pregnancy loss: an update in 2022.
Hum Reprod Open. 2023 Mar 2;2023(1):hoad002. doi: 10.1093/hropen/hoad002. eCollection 2023.
8
COVID-19: Critical appraisal of the evidence.
An Pediatr (Engl Ed). 2021 Sep;95(3):207.e1-207.e13. doi: 10.1016/j.anpede.2021.05.003. Epub 2021 Jul 23.
9
Clinical Practice Guideline: Sudden Hearing Loss (Update).
Otolaryngol Head Neck Surg. 2019 Aug;161(1_suppl):S1-S45. doi: 10.1177/0194599819859885.
10
Evidence-based guideline: unexplained infertility†.
Hum Reprod. 2023 Oct 3;38(10):1881-1890. doi: 10.1093/humrep/dead150.

本文引用的文献

1
[COVID-19: Critical appraisal of the evidence].
An Pediatr (Barc). 2021 Sep;95(3):207.e1-207.e13. doi: 10.1016/j.anpedi.2021.05.019. Epub 2021 Jun 3.
3
SARS Antibody Testing in Children: Development of Oral Fluid Assays for IgG Measurements.
Microbiol Spectr. 2022 Feb 23;10(1):e0078621. doi: 10.1128/spectrum.00786-21. Epub 2022 Jan 5.
5
Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021.
Euro Surveill. 2021 Dec;26(50). doi: 10.2807/1560-7917.ES.2021.26.50.2101147.
6
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
7
Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh.
Science. 2022 Jan 14;375(6577):eabi9069. doi: 10.1126/science.abi9069.
8
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
N Engl J Med. 2022 Jan 6;386(1):35-46. doi: 10.1056/NEJMoa2116298. Epub 2021 Nov 9.
9
Risk factors for poor prognosis in children and adolescents with COVID-19: A systematic review and meta-analysis.
EClinicalMedicine. 2021 Nov;41:101155. doi: 10.1016/j.eclinm.2021.101155. Epub 2021 Oct 19.
10
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
N Engl J Med. 2021 Dec 2;385(23):e81. doi: 10.1056/NEJMoa2108163. Epub 2021 Sep 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验